Merck Serono has launched its RebiSmart self-injection device for patients with multiple sclerosis (MS) in six more countries.

The device will now be available in Spain, Greece, Hungary, Israel, Chile and Colombia, following initial launches in 14 countries in May.

Dr Steven Hildemann, chief medical officer and head of global medical affairs and global drug safety at Merck Serono, said: “With the introduction of MSdialog, we are offering a unique digital technology to provide people with MS a management system that can help them create a more open dialogue with their healthcare team.

After using the device to inject themselves RebiSmart is docked and wirelessly send treatment data such as injection times and doses to the MSdialog server.

The MSdialog system can also be used to prompt patients, via email or text message reminders, to take their medication and it periodically sends out health report questionnaires for patients to answer.

Merck's original RebiSmart was the first injection device in MS to record the date, time and dosage of injections to help healthcare professionals monitor patient adherence.

The device was first launched in countries including Germany, France, the UK and Sweden in May and Merck Serono will continue rolling it out during 2015.

Digital inspiration for pharma on mobile, social media, strategy, best practice, regulations and more